Windlas Biotech

Windlas Biotech IPO Date, Review, Price, Form & Market Lot Details

Windlas Biotech IPO to hit the market on 04 August 2021 and closes on 06 August 2021. The company to raise ₹165 crores via fresh issue and the offer for sale will be 5,142,067 shares as per DRHP, The face value of the Windlas Biotech share is ₹5.
Windlas Biotech IPO date announced, The Windlas IPO to hit the market on 04 August 2021. The company to raise ₹401.54 crores via IPO that comprises fresh issue of ₹165 crores and offer for sale up to 5,142,067 shares of existing share holders. The company incorporated in 2001 based in Dehradun. The registered name of the company is Windlas Biotech Limited (Formerly known as Windlas Biotech Private Limited). They are one of the leading company in pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. They offer pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers. They have over 900 employees with manufacturing facilities in Dehradun. They are doing marketing of their own manufactured authentic nutraceutical, pharmaceutical and ayurvedic products. They are operating with 3 business verticals - 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products) and 3. Exports. Check out Windlas Biotech IPO details.

Customers of Windlas Biotech:
  • Pfizer Ltd
  • Sanofi India Ltd
  • Cadila Healthcare Ltd
  • Emcure Pharmaceuticals Ltd
  • Eris Lifesciences Ltd
  • Intas Pharmaceuticals Ltd
  • Systopic Laboratories Private Limited